

June 11, 2026

California Institute for Regenerative Medicine (CIRM)  
Application Review Subcommittee (ARS)  
Independent Citizens Oversight Committee (ICOC)

**RE: CIRM CLIN2-19526 Grant - Letter of Support for SRN-101 AAV Immuno-Gene Therapy for High-Grade Glioma**

Dear Members of the CIRM ARS/ICOC,

We are writing as California patients, survivors, and family members who have been personally affected by cancer. We represent a range of cancer diagnoses and experiences, and we are united in our support for Siren Biotechnology's work with SRN-101 for high-grade glioma brain cancer patients. Any cancer is a profound disruption to the lives of patients and their families and living with the knowledge that few to no new treatment options exist makes an already difficult experience that much harder. Programs like Siren's give us genuine reason for hope, and we are grateful that organizations like Siren are committed to changing that reality.

As patients and families, we want to speak directly to what makes SRN-101 meaningful from where we sit. Standard treatments for brain cancer like chemotherapy and radiation carry serious side effects that significantly affect quality of life, often leaving patients exhausted, cognitively impaired, and less able to spend meaningful time with our loved ones during an already difficult period. SRN-101 is delivered directly into the tumor in one procedure visit, concentrating its effect where it is needed while minimizing exposure to healthy tissue. This targeted approach has the potential to reduce the treatment burden that conventional therapies impose. Equally important, SRN-101 is a one-time administration, not an ongoing regimen. For patients and families, the difference between a single treatment and weeks or months of repeated clinical visits is enormous. It affects our ability to work, to care for our children, to maintain some semblance of a normal life. A therapy that is both more targeted and less demanding on the patient has the potential to dramatically improve how people experience treatment.

We also want to highlight what we believe is an underappreciated aspect of this program: its potential to reach well beyond high-grade glioma. The platform Siren is working on is applicable to many different types of cancers. The upcoming Phase 1/2 trial in recurrent high-grade glioma is a critical starting point, generating the safety, efficacy, and delivery data that will allow this approach to be tested in additional cancer types. For many of us, the significance of this program extends beyond any single indication. A successful Phase 1/2 trial here creates a foundation for therapies that could ultimately benefit a much larger population of California cancer patients.

Lastly, Siren's genuine commitment to community engagement sets them apart from many early-stage biotechnology companies. Throughout the development of SRN-101, Siren has made deliberate efforts to involve the public in its journey, including communicating openly about its science, engaging with a diverse population of patients and advocates, and ensuring that the communities most affected by cancer have a voice in how this therapy is developed. Most notably, Siren opened a community investment round, giving actual cancer patients and advocates like us - not just institutional investors - the opportunity to become real stakeholders in the direction of this program. This kind of outreach reflects a company that understands its

responsibility to the people it is ultimately trying to help, and it is exactly the model CIRM should want to support.

CIRM was created to fund innovative science that translates into real benefits for Californians. We believe SRN-101 is exactly that. We respectfully urge the committee to support this CLIN2 application.

Respectfully and without a minute to lose,

<b>Name</b>	<b>Connection</b>	<b>City</b>	<b>Personal Statement</b>
Lauren Alderdice, FNP	Patient's family member / Clinician	Nevada City, CA	I am a healthcare provider at a rural public health clinic in California. New options for patients with hard-to-treat cancers are urgently needed!
Dr. Steven Eisenberg	Supporter / Clinician	San Diego, CA	I'm a medical oncologist who sees these patients every single day. We need this innovative therapy STAT!
Alessandro Testori, MD, PhD	Supporter / Clinician	Bakersfield, CA	I have treated several patients afflicted by this horrible condition.
Robert Ritter	Patient	Highland, CA	My brother-in-law died of brain cancer.
Mark Umbach	Patient's family member	--	My mother died of brain cancer.
Gun Landwehr	Patient's family member	Benicia, CA	I am a retired hospice nurse. Do I need to say more? Thank you for working hard and diligently on these horrible cancers.
Abbas Chothia	Patient's family member	Stockton, CA	I am the uncle of the deceased patient, who died of primary high-grade glioma and was only in her early 30s.
Greg Peters	Patient's family member	San Rafael, CA	Glioblastoma is one of the deadliest cancers. We need to move fast with therapies described in this letter. Let's make it happen!
Mark Woods	Supporter	Scotts Valley, CA	Writing in support of my friend, Terri Rutledge, who was diagnosed with glioblastoma six months after suffering a major stroke in December 2023. An investment in clinical trials of SRN-101 has the potential to extend and improve the lives of glioblastoma patients and reduce the burdens on caregivers.
Juan Carlos Soto	Patient's family member	Kensington, CA	A close friend is battling glioblastoma. In the past two weeks, another family member recently succumbed to two highly metastasized cancers. Cancer sucks.
Dan Royer	Patient's family member	Azusa, CA	My son-in-law has survived malignant brain cancer surgery but fears a recurrence.

<b>Name</b>	<b>Connection</b>	<b>City</b>	<b>Personal Statement</b>
Rik Woudwijk	Supporter	Rancho Palos Verdes, CA	I have two close friends with brain cancer and fully support Siren to increase their chance of survival, and hopefully many others.
Michael Baird	Patient's family member	Morro Bay, CA	--
Andrew Ward	Patient's family member	San Diego, CA	--
Roberta Blair Thompson, DC	Patient's family member	Stanton, CA	--
Ju Park	Supporter	Los Angeles, CA	--
Travis McClintic	Patient's family member	San Francisco, CA	--
York Huang	Patient's family member	San Jose, CA	--
Greg Mack	Supporter	Long Beach, CA	--
Richard Harmon	Patient's family member	Walnut Creek, CA	--
Raf Podowski	Patient's family member	Pleasant Hill, CA	--
Michael Ventnor	Patient's family member	Lafayette, CA	--
Scott Paterson	Patient's family member	Menlo Park, CA	--
Kristine Enea	Supporter	San Francisco, CA	--
Carol Alderdice	Supporter	Nevada City, CA	--
Dawn Nguyen	Patient's family member	Anaheim, CA	--
Vivek Mungali	Supporter	Belmont, CA	--
Babak Baradaran	Supporter	Trabuco Canyon, CA	--
Anthony Gallardo	Supporter	Fontana, CA	--
Evan Smith	Supporter	Fair Oaks, CA	--
Jonathan Wright	Patient's family member	San Francisco, CA	--
Prakash Sripathy	Patient's family member	Cupertino, CA	--
Romain Bouziat	Patient's family member	San Francisco, CA	--
Ricardo Rodriguez	Supporter	Lake Forest, CA	--
Joanne Tang	Supporter	San Francisco, CA	--
Cynthia Mocko	Supporter	Stockton, CA	--
Jason Rivera	Patient's family member	San Francisco, CA	--
Everett Moiseff	Patient's family member	San Diego, CA	--
Andrew Kaminski	Patient's family member	Culver City, CA	--
Jim Schindler	Supporter	Irvine, CA	--
Al Ortiz	Supporter	Torrance, CA	--
Donnis Stradley	Patient's family member	Clayton, CA	--
Maria Ortiz	Supporter	Clovis, CA	--

<b>Name</b>	<b>Connection</b>	<b>City</b>	<b>Personal Statement</b>
Walter O'Brien	Supporter	Murrieta, CA	--
Leon Kelly	Patient's family member	Folsom, CA	--
Robert Kneen	Cancer survivor	El Dorado Hills, CA	--
Randy Lim	Cancer survivor	San Francisco, CA	--
Jaso Nakatani	Patient's family member	Los Angeles, CA	--
Anca Duquette	Patient's family member	Kenwood, CA	--
Jim Laitner	Supporter	Santa Rosa, CA	--
Hartwig Adam	Patient's family member	Marina del Rey, CA	--
Jurgen Jandeleit	Supporter	Pleasanton, CA	--
Erlinda Jandeleit	Supporter	Pleasanton, CA	--
Neema M.	Supporter	San Francisco, CA	--
Don Basanes	Patient's family member	Fairfield, CA	--
Anthony Young	Supporter	Los Angeles, CA	--
Jacob Theil	Patient's family member	Woodland, CA	--
Scott Clough	Supporter	San Juan Capistrano, CA	--
Richard Hoey	Supporter	Lancaster, CA	--
Thomas Mueller	Supporter	Anaheim, CA	--
Raghu Subramanian	Patient's family member	San Ramon, CA	--
Christophe Paillart	Patient's family member	San Francisco, CA	--
Scott Ogden	Supporter	Roseville, CA	--
Gary Baughman	Supporter	Newcastle, CA	--
Ronald Mattarolo	Patient's family member	Grass Valley, CA	--
Karonie Mattarolo	Supporter	Grass Valley, CA	--
Pedro Munoz	Supporter	Chula Vista, CA	--
Dominic Valdez	Patient's family member	Fresno, CA	--
Meister	Supporter	Livermore, CA	--
Gary Pashby	Patient's family member	Arroyo Grande, CA	--
Jate Samathivathanachai	Supporter	Belmont, CA	--
Yash Rathod	Supporter	San Francisco, CA	--